Product Images Migranal

MIGRANAL is a nasal spray intended only for nasal use to treat headaches. Each 1 mL of MIGRANAL contains 4 mg of dihydroergotamine mesylate. The product must not be injected and is only intended for use with a special nasal sprayer. The kit includes instructions for administration and a package insert for further information. The product must be stored below 25° Celsius (77°F) and should not be frozen or refrigerated, while the sprayer must be discarded after treatment or after eight hours of use.*

This is a graph (Figure 1) that shows the estimated probability of a patient responding to MIGRANAL® Nasal Spray (dihydroergotamine mesylate) as a function of time since the first dose during a four-hour period. The response rate is compared to placebo (MIGRANAL® N=208, Placebo N=200) and is displayed as a percentage. The response rate is highest at 80% within the first hour and decreases steadily over the four-hour period.*

This appears to be a graph showing the percentage of patients who had a positive response to MIGRANAL® (dihydroergotamine mesylate) Nasal Spray during the four hours following dosing, based on studies 3 and 4 involving 97 patients who received the medication and 100 who received a placebo. The x-axis showcases the time since the first dose in hours, while the y-axis shows the percentage of responders.*

The figure shows the estimated probability of patients using the analgesic MIGRANAL® (dihydroergotamine mesylate) Nasal Spray 2 mg or placebo to treat migraine over the 24 hours following the first spray. The probabilities are displayed for each hour and range from 0% to 100%. The data was collected from a sample of 305 patients who used MIGRANAL® and 300 who used placebo.*

Dihydroergotamine mesylate is a chemical compound with a molecular formula of C20H25N3O4S and a molecular weight of 679.78 g/mol. No further information is available from the given text.*